Oncolytic Virus Approval in Japan Marks New Era in GBM Care
Glioblastoma Multiforme Market Poised to Reach USD 4.5 Billion by 2031, Driven by R&D Surge and Rising Disease Burden in the US and Japan
The Global Glioblastoma Multiforme (GBM) Market reached USD 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 4.5 billion by 2031. The market is expected to exhibit a compound annual growth rate (CAGR) of 8.6% during the forecast period 2024–2031. The global GBM market is a dynamic and fast-evolving industry dedicated to diagnosing, treating, and managing GBM—a highly aggressive and life-threatening brain tumor requiring advanced therapeutic solutions.
Get Free Sample Report Here:
https://datamintelligence.com/download-sample/glioblastoma-multiforme-market
Market Overview
- Market Size (2022): USD 2.4 Billion
- Forecast (2031): USD 4.5 Billion
- CAGR (2024–2031): 8.6%
- US Market Growth: From USD 682 Million (2023) to USD 1.44 Billion (2033) at 7.8% CAGR
- Japan Market: USD 230 Million (2022) to USD 390 Million (2033), 6.8% CAGR
Market Drivers and Growth Opportunities
1. Rising Incidence and Aging Populations
GBM incidence rises with age, affecting approximately 3.2 individuals per 100,000 annually. Aging populations, particularly in Japan and the US, are significantly increasing demand for advanced GBM therapies.
2. Rapid Advancements in Targeted Therapies
The market is witnessing an influx of innovations including tumor treating fields (TTF), immunotherapies (PD-1 inhibitors, dendritic cell vaccines), and targeted therapies. CAR-T and gene therapies are revolutionizing treatment paradigms.
3. Increased R&D Funding
Growing interest from pharmaceutical giants and government agencies has boosted investments in GBM-specific trials. Companies like Gilead, Merck, Roche, and Bristol-Myers Squibb are at the forefront of innovation.
4. Regulatory Support and Orphan Drug Designation
The U.S. FDA and Japan’s PMDA provide incentives such as fast-track approvals and market exclusivity, making GBM treatment development commercially attractive.
5. Unmet Clinical Needs
The aggressive nature of GBM, high recurrence rate, and limited survival outcomes (~14–15 months median survival) create pressing demand for next-generation therapies.
Speak to Our Senior Analyst and Get Customization in the report as per your requirements:
https://datamintelligence.com/customize/glioblastoma-multiforme-market
Regional Insights
United States
The U.S. holds the largest market share, driven by advanced healthcare infrastructure, clinical trial activity, and early adoption of novel therapies. The GBM market in the U.S. is expected to more than double by 2033, growing from USD 682 million in 2023 to over USD 1.4 billion.
Japan
Japan's GBM market was valued at USD 230 million in 2022 and is projected to reach USD 390 million by 2033. The country's aging population and rising healthcare spending are fueling adoption of new treatment protocols and technologies.
Latest Industry Trends
CAR-T Therapy Breakthroughs
In 2024, Gilead/Kite Pharma reported promising early-phase results for a dual-target CAR-T therapy against EGFR and IL-13Rα2. The treatment showed tumor shrinkage in 62% of patients with recurrent GBM. While challenges remain in extending response duration, this represents a significant step in solid-tumor CAR-T progress.
Tumor Treating Fields (TTF) on the Rise
Non-invasive TTF therapy, pioneered by Novocure, is gaining mainstream adoption in the U.S. and Japan. When used alongside temozolomide, TTF has shown significant survival advantages and is being increasingly integrated into standard of care.
Pipeline Expansion
Several targeted therapies—including DNX-2401 (oncolytic virus), VAL-083 (alkylating agent), and MDNA55 (immunotoxin)—are progressing through Phase II/III trials globally. Many of these are focused on recurrent GBM, where treatment options remain limited.
Buy the exclusive full report here:
https://datamintelligence.com/buy-now-page?report=glioblastoma-multiforme-market
Challenges Ahead
- Blood-Brain Barrier Limitations: Drug delivery remains complex due to limited permeability. Innovative delivery methods, such as convection-enhanced delivery and nanoparticle platforms, are under active development.
- Tumor Heterogeneity: GBM tumors vary widely in genetic makeup, often rendering single-target therapies ineffective.
- Short Duration of Treatment Response: Despite advancements, recurrence and progression rates remain high.
Future Outlook
With several high-potential therapies on the horizon and strong support from regulatory bodies, the GBM market is entering a transformative phase. Collaborative research initiatives, rising patient awareness, and integration of AI into diagnostic imaging are expected to further accelerate market momentum.
Stay informed with the latest industry insights-start your subscription now:
https://datamintelligence.com/reports-subscription
Key Companies to Watch
- Roche
- Merck & Co.
- Bristol-Myers Squibb
- Gilead Sciences (Kite Pharma)
- Novocure
- Denovo Biopharma
- Kazia Therapeutics
- Amgen
- Samsung Bioepis
|
Market Summary Table |
||||||||||||||||
|
DataM Intelligence is a global market research and consulting firm offering comprehensive business solutions from initial research through to strategic consulting. We empower clients with timely, data-driven insights drawn from key trends and industry developments.
Our extensive research library includes over 6,300 reports spanning 40+ industries, helping more than 200 organizations across 50+ countries meet their strategic goals. Whether through syndicated or customized reports, our proven methodologies ensure impactful decision-making support tailored to your business needs.
At DataM Intelligence, we specialize in delivering end-to-end market research and consulting solutions designed to unlock your business potential. By harnessing proprietary insights, market trends, and breakthrough developments, we craft intelligent strategies that drive results.
With a repository of 6,300+ detailed reports across 40+ sectors, we’ve helped over 200 global businesses across 50+ nations achieve growth. From syndicated analysis to tailored research, our dynamic approach addresses the critical intelligence your business needs to thrive.
DataM Intelligence is a premier provider of market research and consulting services, offering a full spectrum of business intelligence solutions—from foundational research to strategic consulting. We utilize proprietary trends, insights, and developments to equip our clients with fast, informed, and effective decision-making tools.
Our research repository comprises more than 6,300 detailed reports covering over 40 industries, serving the evolving research demands of 200+ companies in 50+ countries. Whether through syndicated studies or customized research, our robust methodologies ensure precise, actionable intelligence tailored to your business landscape.
Contact US:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian